Stock Financial Ratios, Dividends, Split History

CIO / City Office REIT Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price12.76
Volume342,300.00
Market Cap ($M)466.47
Enterprise Value ($M)869.38
Book Value ($M)396.63
Book Value / Share10.98
Price / Book1.18
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 4,480,000
Common Stock Shares Outstanding 36,012,086
Common Shares Outstanding 36,118,163
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.01
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Assets860.03
Liabilities463.10
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues106,487,000.00
Operating Income15.21
Net Income9.16
Earnings Per Share Diluted-0.05
Earnings Per Share Basic-0.05
Earnings Per Share Basic And Diluted-0.05
Cash Flow Statement (mra) ($M)
Cash From Operations36.55
Cash from Investing-244.78
Cash from Financing36.55
Identifiers and Descriptors
CUSIP178587101
Central Index Key (CIK)1593222
Related CUSIPS
178587200

Split History

Stock splits are used by City Office REIT Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

5 Russell 3000 Top Dogs Fetch >24% Net Gains Per Brokers To July 2019

9h seekingalpha
"All Russell US Indexes are subsets of the Russell 3000 Index, [namely] large-cap Russell 1000 & small-cap Russell 2000 Indexes. These Indexes are. building blocks of financial-products [and] performance-benchmarks." - FTSE Russell. (17-0)

Can City Office REIT Deliver The Goods?

2018-07-11 seekingalpha
We are maintaining our STRONG BUY recommendation and we believe that as CIO’s dividend becomes safer (payout ratio under 100%) and the valuation gap should tighten. (2-0)

City Office Has A Healthy Mix Of Value And Growth

2018-06-07 seekingalpha
City Office REIT (NYSE:CIO), which buys and operates office properties in the southern and western U.S., has become attractive as its share price has dipped below that of a recent issuance. Well-located properties should fuel NOI and bottom line growth in excess of what is implied by the current FFO multiple. Essentially, CIO is positioned as a growth company but trades like a value stock, leaving substantial room for outperformance. (3-0)

City Office REIT - An AFFO Bridge Too Far

2018-05-29 seekingalpha
City Office REIT (CIO) is a small, Canadian based REIT that specializes by “owning and operating high-quality office properties located primarily in metropolitan areas in the Southern and Western U.S." (2-0)

Maintaining Strong Buy Thesis For City Office

2018-05-08 seekingalpha
Owning small-cap stocks creates volatility and one way for me to smooth out the instability is to reduce exposure to one company. (10-0)

CUSIP: 178587101